Open AccessThe Role of PINP in Diagnosis and Management of Metabolic Bone Disease
Author(s) -
Melissa J Gillett,
Samuel Vasikaran,
Charles Inderjeeth
Publication year - 2021
Publication title -
pubmed central
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 28
pISSN - 0159-8090
DOI - 10.33176/aacb-20-0001
Subject(s) - medicine , n terminal telopeptide , osteoporosis , bone remodeling , denosumab , bone resorption , parathyroid hormone , endocrinology , bone disease , oncology , osteocalcin , alkaline phosphatase , calcium , biochemistry , chemistry , enzyme
Serum procollagen type I N-propeptide (PINP) is designated the reference marker of bone formation in osteoporosis; the reference marker for resorption is C-terminal telopeptide of type I collagen (CTX). PINP has very low circadian and biological variation, is not affected by food intake, and is very stable in serum after venepuncture. The two automated commercial assays for PINP provide similar results in subjects with normal renal function, allowing reference intervals to be used interchangeably. Bone turnover markers (BTM) are currently not recommended for fracture risk assessment and therefore not included in fracture risk calculators. In the management of osteoporosis, the main utility of BTM including PINP is for monitoring therapy, both antiresorptive as well as anabolic agents; monitoring is thought to help improve adherence. PINP as well as CTX may also be used in assessing offset of drug action following a pause in bisphosphonate therapy, to help decide when to re-instate therapy, or following cessation of denosumab therapy to assess efficacy of follow-on bisphosphonate therapy. PINP may also be used in the diagnosis of Paget's disease of bone as well as in monitoring response to therapy and for recurrence. Although BTM other than bone alkaline phosphatase are currently not recommended for use in metabolic bone disease of chronic kidney disease, PINP measured by assays specific to the intact molecule has potential in this condition. Further studies are needed to examine this area, as well as in malignant bone disease.